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Abstract
Background: In the past 15 years, impressive progress has been made to understand the molecular mechanism behind
aneuploidy, largely due to the effort of using various -omics approaches to study model systems (e.g. yeast and mouse
models) and patient samples, as well as the new realization that chromosome alteration-mediated genome instability
plays the key role in cancer. As the molecular characterization of the causes and effects of aneuploidy progresses, the
search for the general mechanism of how aneuploidy contributes to cancer becomes increasingly challenging: since
aneuploidy can be linked to diverse molecular pathways (in regards to both cause and effect), the chances of it being
cancerous is highly context-dependent, making it more difficult to study than individual molecular mechanisms. When so
many genomic and environmental factors can be linked to aneuploidy, and most of them not commonly shared among
patients, the practical value of characterizing additional genetic/epigenetic factors contributing to aneuploidy decreases.
Results: Based on the fact that cancer typically represents a complex adaptive system, where there is no linear relationship
between lower-level agents (such as each individual gene mutation) and emergent properties (such as cancer phenotypes),
we call for a new strategy based on the evolutionary mechanism of aneuploidy in cancer, rather than continuous analysis of
various individual molecular mechanisms. To illustrate our viewpoint, we have briefly reviewed both the progress and
challenges in this field, suggesting the incorporation of an evolutionary-based mechanism to unify diverse molecular
mechanisms. To further clarify this rationale, we will discuss some key concepts of the genome theory of cancer evolution,
including system inheritance, fuzzy inheritance, and cancer as a newly emergent cellular system.
Conclusion: Illustrating how aneuploidy impacts system inheritance, fuzzy inheritance and the emergence of new systems
is of great importance. Such synthesis encourages efforts to apply the principles/approaches of complex adaptive systems to
ultimately understand aneuploidy in cancer.
Keywords: Adaptive system, Aneuploidy, Cancer evolution, Complexity, Emergence of new genome, Fuzzy inheritance,
Genome theory, Non-clonal chromosome aberrations (NCCAs), Punctuated evolution, System inheritance
Background and progress
Why is aneuploidy commonly observed in various cancer
types? How does aneuploidy directly or indirectly contrib-
ute to cancer? Is aneuploidy good or bad for cancer initi-
ation and progression, and how does it affect treatment
response? What is the relationship between aneuploidy
and other genetic/epigenetic aberrations? How important
is it to study each individual molecular mechanism that
can be linked to aneuploidy? What are the general mecha-
nisms (cause and effect) for generating aneuploidy? Why
can aneuploidy be detected from other diseases? And
what is the biological significance of aneuploidy in normal
tissues for normal individuals? … These questions repre-
sent some long-debated issues in the field of cancer
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research, ever since Theodor Boveri recognized the link
between aneuploidy and cancer over a century ago [1–4].
Specific aneuploidy has been observed in various non-
cancer diseases: Down syndrome with trisomy chromo-
some 21, Edwards syndrome with trisomy 18, Patau
syndrome with trisomy 13, Klinefelter’s syndrome with
an extra X, and Turner’s syndrome with the absence of
one X. While clonal aneuploidy is also detected in some
cancers, such as chronic lymphocytic leukemia (CLL)
with trisomy 12 and acute myeloid leukemia (AML) with
trisomy 8, the percentage of such cancer patients with
the signature clonal aneuploidy is much lower (18% for
CLL and 8.5% for AML) compared to those with Down
syndrome (over 95% of all patients), suggesting that
there are more diverse genomic factors contributing to
cancer (even for the liquid cancer type) than those non-
cancer genetic diseases.
Altogether, the complexity of aneuploidy makes study-
ing its relationship with cancer extremely challenging
(Table 1). Some known complications include: a) most
cancer cases display non-clonal aneuploidy (impeding the
fact that clonal aneuploidy has been much more com-
monly researched for decades) [5–9], b) aneuploidy often
occurs in combination with other types of genetic/epigen-
etic and genomic aberrations (translocations and poly-
ploidy) (Table 2) c) there is often a variable degree of
somatic mosaicism [10–13], and d) there is a complex, dy-
namic relationship between aneuploidy and genome in-
stability (Table 3). Interestingly, many common and
complex diseases have been linked to non-clonal aneu-
ploidy and somatic mosaicism as well [14, 15], which has
led to efforts to search for commonly shared mechanisms
among different diseases or illness conditions [16–19]. It
is worth noting that aneuploidy can also be detected from
the normal developmental process [20–22].
Such complexity did however discourage aneuploidy
research, as cloning and characterizing individual cancer
genes had promised much more certainty. During the
peak era of oncogene- and tumor suppressor gene-
focused research, for example, the importance of aneu-
ploidy was largely ignored, due to high expectations
from the gene mutation theory of cancer. As a result, ef-
forts to systematically study aneuploidy in cancer, espe-
cially based on the belief that aneuploidy is much more
important than gene mutations, are limited to a small
number of research groups [23–26]. One of the popular
viewpoints was that cancer gene mutations hold the key
to understanding cancer, whereas chromosomes were
just vehicles of genes; it was furthermore argued that
most chromosomal changes are either incidental or the
consequence of gene mutations.
While it was observed that some chromosomes display
a tumor suppressor function following cell/chromosome
fusion experiments [27], efforts were focused on cloning
tumor suppressor genes [28]. The lack of easy-to-
recognize patterns in aneuploidy has certainly reduced the
enthusiasm of most funding agents about this topic, espe-
cially when gene mutation research has promised to iden-
tify the key common gene mutations for cancer.
One important publication has classified cancer into
two major types based on observed molecular mecha-
nisms: chromosome instability (CIN) and microsatellite
Table 1 Explanations of key terminologies
Aneuploidy is a changed genomic state with an abnormal number of
chromosomes in a cell. In cancer, most aneuploidy is not clonal or
constitutional. Recently, a looser definition of aneuploidy has been used
to analyze DNA sequence data, which includes partial chromosomal
changes and somatic copy number aberration (SCNA). Such usage is
not precise, as germline CNVs and SCNA represents the variable copy
number of specific sequences, which is not the same as the entire
abnormal chromosome(s). According to the genome theory, the
chromosome represents a coding system, so the impact of aneuploidy
is therefore much more significant than SCNA. The mechanisms causing
somatic aneuploidy are many; examples can be found in Table 2.
CIN: Chromosome instability (CIN) refers the rate (cell-to-cell variability) of
changed karyotypes of a given cell population. There are two types of CIN:
numerical and structural. Numerical CIN is determined by the gain or loss
of whole chromosomes or fractions of chromosomes (aneuploidy), as well
as other forms. Structural CIN, on the other hand, is determined by
structural NCCAs. Numerical and structural CIN often co-exist. CIN can be
effectively measured by the frequency and type of NCCAs.
Type I and type II CIN: CIN can be classified into two types based on its
involved molecular mechanisms. Type I CIN is directly linked to the
maintenance of genome integrity within the chromosomal cycle,
including the chromosomal machinery, checkpoints, and repair systems
(see Table 3). Type I CIN is often detected in chromosome instability
syndromes which provide good examples of direct “molecular causative
relationship” between identified genes and CIN. However, mutations to
type I genes are rare and they do not explain sporadic cancer. In contrast,
the mechanisms of type II CIN are often associated with non-genetic
factors such as the micro-environment and physiological processes, which
do not have a direct molecular causative explanation. The diverse type II
mechanisms all share one common feature: they are involved in the
cellular system’s response to stress, increasing heritable changes [50].
Fuzzy inheritance: In contrast to the gene theory, which states that a
gene codes for a specific, fixed phenotype, the genome theory suggests that
most genes code for a range of potential phenotypes. From this “fuzzy”
range of phenotypes, the respective environment can then allow the best-
suited status to be “chosen” [4, 37, 59]. For example, the gene for pea color
codes for an entire potential spectrum of colors, from yellow to intense
green (including blends of yellow and green, or green with yellow spots),
not just two fixed, distinctive colors (yellow or intense green). In cancer, the
emergence of “genomic context” adds yet another layer of complexity and
instability that pushes fuzzy inheritance’s dynamics to a maximal status.
Macro-and micro-cellular evolution: Macro-cellular evolution refers to
karyotype change-mediated somatic cell evolution, which alters the
genome context of a given cellular system. In contrast, micro-cellular
evolution refers to gene/epigene change-mediated evolution, which
modifies a given cellular system within the same karyotype. Macroevolution
and microevolution respectively refer to organismal evolution at the above-
species level and at the population level within a species.
System inheritance: Unlike the gene-defined “parts inheritance” (the
instructions for making a given protein or RNA), a new three-dimensional
genomic topologic coding, or the blueprint of the genome, is defined by
the order of genes or other DNA sequences along and among the
chromosomes of a given genome. This blueprint encodes how genes
interact as an emergent property, which provides the instructions for how
genomic networks work [4, 37, 66].
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instability [29]. Remarkably, the majority of colon can-
cers display CIN. The fact that most cancers can be
linked to chromosomal instability was a surprise to
many who primarily study cancer genes.
If the majority of cancers are linked to CIN, and aneu-
ploidy contributes to CIN, more attention needs to be
paid to aneuploidy [30]. Based on this concept, increased
efforts were focused on identifying genes that are re-
sponsible for aneuploidy. Many individual genes and
molecular pathways involving chromosomal machinery/
integrity have been linked to aneuploidy. For example, a
list of identified genes that contribute to aneuploidy-
mediated cancer includes germline BUBR1 mutation,
which leads to aneuploidy and cancer predisposition
[31]. Additional examples can be found in Table 2.
Another important factor that promotes aneuploidy re-
search is the popularization of copy number variation stud-
ies of the human genome [32–34]. If various individual
instances of CNV are of importance, large scale CNVs
caused by aneuploidy should be too, despite the fact that
the search for specific genes related to aneuploidy (such as
chromosome 21) have traditionally been the main focus.
The availability of various technologies that can detect
CNV have now revolutionized molecular cytogenetics. It
should be mentioned that the cytogenetically visible copy
number variations (CG-CNVs) need more attention [35].
Regarding the framework of fuzzy inheritance, CNVs, CG-
CNVs, small supernumerary marker chromosomes and an-
euploidy represent different degrees of fuzziness, which are
likely reflected by quantitative difference or combinational
effect. It is important to integrate these with analyses of sys-
tem emergence [4, 36, 37].
Table 2 Examples of different types of causative factors of
aneuploidy
1. Gene mutations/epigenetic alterations [111–113]
Mitotic checkpoint defects, e.g. BUB1, MAD1 and
CENPE
[114, 115]
Microtubule attachment defects, e.g. aurora kinase B,
Cydlin A,
Mitotic spindle and centrosome defects [116]
Other CIN-related mutation, e.g. p53, ATM [117]
2. Stress- (physiological, pathological and pharmaceutical)
related responses
Defective mitotic figures (condensation defects)
(DMF, sticky chromosomes)
[50, 78, 106]
Chromosome fragmentations (C-Frags) [115, 116]
Genome chaos [5, 6, 37, 59,
67]
Chromosomal cycle variations (replication,
condensation, segregation, de-condensation)
[104]
Non-specific stress (triggers type II CIN) [50]
3. Genome system variability
Fuzzy inheritance [4, 37, 59]
Cellular adaptation [37, 95]
Survival under high stress [56, 67]
To illustrate the viewpoint that many genomic and environmental factors can
contribute to aneuploidy, a few examples are presented, among a large
number of publications. We focus more on the examples that feature a
cytogenetic perspective, as these are currently less popular compared to gene
mutation studies, despite their importance
Table 3 Examples of interesting observations in aneuploidy
studies including some conflicting data. Some comments are
also offered to explain them
1. The dynamic relationship between aneuploidy and CIN
Aneuploidy generates CIN, including increased chromosome loss,
mutation rate and defective DNA damage repair [39, 119].
The relationship between aneuploidy and CIN can be envisioned as a
“vicious cycle,” wherein one potentiates the other [120].
The “stress–CIN–cancer evolution relationship” can also be used to
discuss the relationship between aneuploidy and cancer [50].
Elevated transcriptome dynamics are linked to karyotype changes which
impact multiple genetic/epigenetic interactions [121–123]
Aneuploidy is less influential compared to structure alterations [54].
CIN rates might be more predictive for tumor outcome than assessing
aneuploidy rates alone [54, 124].
Many cancer cell lines with aneuploidy are relatively stable (an example
of fuzzy inheritance of some relatively stable systems) [37].
Genome chaos, including karyoplast budding, giant cells and mitotic
catastrophe, is often associated with aneuploidy [67, 125–127].
Chromosomal condensation defects (DMFs) and Chromosome
fragmentation (C-Frags) can generate aneuploidy [37, 106, 118].
Aneuploidy (in the form of mosaicism) represents a common
phenomenon. We may all have a touch of Down syndrome [128, 129].
Aneuploidy is a main feature among individual cancer cell lines. The
rate of aneuploidy seems inherited [72].
Genomic PTEN deletion size influences the landscape of aneuploidy and
outcome in prostate cancer [130].
ATM and p21 cooperate to suppress aneuploidy and tumor
development [117]
2. The complex relationship between aneuploidy and immune response
When co-cultured with natural killer cells, aneuploidy cells with complex
karyotype-induced senescent cells were selectively cleared [131].
High copy number alterations in melanoma patients are linked with less
effective response to immune checkpoint blockade anti–CTLA-4 [52].
3. Biological impact of aneuploidy
Aneuploidy changes the genomic coding, which affects the
transcriptome, proteome, network structure, incidence of CIN and
phenotypes [4, 37, 132].
Chromosome mis-segregation per se can alter the genome in many
ways in addition to chromosome gain or loss [133].
Aneuploidy puts pressure on the protein machinery and quality control,
which generates a global stress response, reducing cell proliferation [133].
Both specific gene effects and the typical aneuploidy stress response
contribute to new genomic coding or/and increased system stress,
which can impact the emergent process of cancer evolution ([133],
current paper)
Karyotype status (e.g. aneuploidy and polyploidy) can restore functions
of specific genes (e.g. MYO1). Thus, genomic coding changes gene
coding [83].
The chromosomal size involved in aneuploidy is inversely correlated to
the resulting fitness [134].
The risk of cancers to metastasize is proportional to the degree of
cancer-specific aneuploidy [48].
There is a dynamic relationship between epigenetic events and
aneuploidy; epigenetic marks play a role in the control of chromosome
segregation and integrity; aneuploidy impacts chromatin silencing
[135–137].
New approaches are needed to study the complexity of systems, including
that of aneuploidy-mediated karyotype evolution [138, 94, 110].
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In recent years, due in part to the disappointment that has
come from attempting to identify the common driver gene
mutation, and more significantly, due to the realization that
genome instability plays an important role in cancer, aneu-
ploidy studies have gained momentum. In particular, the
popularity of studying aneuploidy in cancer has been pro-
moted by some yeast biologists. Taking advantage of yeast
model systems, they have applied cutting-edge molecular
and genomic technologies to illustrate the molecular mecha-
nisms that link aneuploidy to biological functions [38–42];
by translating their discoveries into cancer research, they
have brought the spotlight on aneuploidy research in cancer
[43, 44] (Tables 2, 3). Interestingly, a complex relationship
between aneuploidy and cancer has also been revealed, pro-
posing that aneuploidy can either promote or inhibit cancer
progression depending on the evolutionary context. This has
led to the paradox of aneuploidy in cancer [45, 46].
There have been attitude changes towards the study of
aneuploidy as well. When direct evidence simultaneously
characterized gene mutation and chromosomal aberra-
tions as drivers for the phenotypic implication of metas-
tasis [47], the authors clearly emphasized CIN, and the
potentially involved gene was not even mentioned in the
title. This likely represents a new favored approach fo-
cusing on genome-level changes. There is also the
realization that chromosomal aberrations contribute
more significantly to metastasis than gene mutations do
[48] which supports the hypothesis that chromosomal
aberration-mediated genome evolution is responsible for
all major transitions in cancer evolution, including me-
tastasis and drug resistance [49, 50]. Furthermore, and
surprisingly to many molecular researchers, chromo-
some aberration profiles have been demonstrated to
have a much stronger prediction value in the clinic com-
pared to DNA sequencing profiles [51]. This conclusion
has gained strong support from various cancer genome
sequencing projects [52, 53], which prompts an import-
ant question regarding the differential contribution of
chromosome aberrations and gene mutations to the can-
cer genotype. All together, rapidly accumulated data has
forcefully highlighted the importance of aneuploidy in
current cancer research, and more detailed molecular in-
formation linking individual gene mutations or epigen-
etic events to aneuploidy will soon flourish.
Challenges for predicting cancer status based solely on
the molecular mechanisms of aneuploidy
Like other hallmarks of cancer, aneuploidy has now be-
come a hot topic. A predictable new trend is that more
researchers will join the effort to link all possible gen-
etic/epigenetic and environmental factors to aneuploidy
and cancer. However, as we have extensively discussed,
due to biocomplexity (i.e. that many individual factors
can contribute to the same phenotype), it is possible that
merely collecting more diverse molecular data linking
gene mutation and environmental factors to aneuploidy
is not the best way to advance this field. This is because
there will be too many factors involved, most of them
lacking the power to predict cancer status [54, 55].
This viewpoint has been articulated by the evolutionary
mechanism of cancer and its relationship with individual
molecular mechanisms [50, 56]. In brief, cancer evolution
can be understood by the dynamic interaction among four
key components: internal and external stress; elevated gen-
etic and non-genetic variations (either necessary for cellular
adaptation or resulting from cellular damages under stress);
genome-based macro-cellular evolution (genome replace-
ment, emergent as new systems); and multiple levels of sys-
tem constraint which prevent/slow down cancer evolution
(from tissue/organ organization to the immune system and
mind-body interaction). Since the sources of stress are un-
limited and unavoidable (as they are required by all living
systems), there are large numbers of gene mutations/epigen-
etic events/chromosomal aberrations, such as aneuploidy,
that can be linked to stress-mediated genomic variants; fur-
thermore, as environmental constraints are constantly chan-
ging, even identical instances of aneuploidy will have
completely different outcomes in the context of cancer evo-
lution, as the results of each independent run of evolution
will most likely differ. Solely knowing the mechanism of an-
euploidy limits the predicting power for cancer. Further-
more, hundreds of gene mutations can contribute to
aneuploidy, and the various contexts of cancer evolution are
almost unlimited. Based on this rationale, we promote the
idea of using the evolutionary mechanism of cancer to unify
diverse individual molecular mechanisms of cancer (4).
Unfortunately, such ideas have received little attention
within the cancer research community, due in part to the
traditional molecular characterization of gene mutations,
and possibly more so due to many cancer biologists’ un-
familiarity with complexity science and a lack of under-
standing of the key principles of bio-emergence. It is thus
necessary to discuss this issue of aneuploidy in cancer
using the framework of the complex adaptive system [37].
A complex adaptive system is a system made up of
many individual parts (agents) with nonlinear dynamical
interaction. Due to the key emergent relationship be-
tween the lower level of heterogeneous agents and the
behavior of the entire system, a detailed understanding
of the individual parts does not automatically convey a
determinist’s understanding of the whole system’s behav-
ior. There are no fixed, dominant agents within the
adaptive system, and when agents of the system are
changed, the system adapts or reacts. Moreover, small
changes in initial conditions can generate large changes
in the system’s outcome, and stochasticity is also fre-
quently involved [57, 58]. As a result, the reductionist
approaches which have triumphed in molecular biology
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may be fundamentally limiting when attempting to
understand complex adaptive systems.
Cancer is typically a complex adaptive system involv-
ing multiple levels of agent interactions and genotype/
phenotype emergence among different types of tissue/
organ constraints. In such a system, aneuploidy repre-
sents only one type of agent, despite its importance.
There is a complex interaction among different levels of
genetic organization, which involves phase transitions
among clonal and non-clonal cellular populations, and
the final emergence of different genome-defined cellular
systems under highly dynamic cellular environments and
the process of cancer evolution. This reality of cancer
evolution explains why it is so challenging to predict the
final phenotype based on an understanding of one type
of agent. The take-home message is that simply under-
standing the molecular mechanism (both cause and ef-
fect) of aneuploidy is far from enough. A better strategy
is to monitor the evolutionary process by measuring
evolutionary potential. For example, the overall degree
of CIN is more predictive than individual gene mutation
profile [54]; large-scale chromosomal structural aberra-
tions can often have a more profound impact on cancer
evolution (even though aneuploidy often leads to struc-
tural aberrations as well); and the landscape of chromo-
somal aberrations is more predictive than gene mutation
landscapes. Furthermore, the initial factor and the evolu-
tionary trajectory differ in complex systems. It is now ac-
cepted that treatment options can often drastically and
rapidly change the genetic landscape of the cancer [59].
In addition to the challenge that cancer is a complex
adaptive system, it should be understood that current
molecular knowledge of aneuploidy is mainly derived
from model systems, which can differ from cancer sys-
tems in patients. The following limitations are briefly
mentioned to bring the reader’s attention to them, and
they are also useful for explaining some conflicting ob-
servations. First, the platform of the yeast model differs
from human cellular populations within tissue. Different
species display the feature of aneuploidy quite variably.
In budding yeast Saccharomyces cerevisiae, aneuploidy is
not uncommon and exists in natural populations; in
plants, organisms can tolerate whole chromosome aneu-
ploidy without triggering CIN; in mice, every single
whole chromosome gain or loss is embryonic lethal [60];
in humans, the situation is similar to that of mice, with
the exception of a few chromosome gains such as 13, 18
and 21. The pattern of evolution also differs when di-
verse types of cellular selection are involved, in addition
to differing types of system constraints. For cancer evo-
lution in reality, the overall complexity and the level of
dynamics is much higher, which can often change the
game completely. In the future, multiple cellular models
might be helpful to certain degrees, especially when the
time variable (i.e. development and aging) is added in to
the equation.
Second, the status of clonal and non-clonal aneuploidy
differs between many model systems and the reality of
cancer. So far, for many yeast and human cell models,
aneuploidy stains are created with clonal populations in
which most cells display the same extra chromosomes.
In contrast, for many solid tumors, aneuploidy exists in
non-clonal forms. Such differences may contribute to
some misperceptions, thus requiring further studies. For
example, the analysis of trisomic cells from human pa-
tients with congenital aneuploidy syndromes did not dis-
play any increased CIN, concluding that aneuploidy
itself does not lead to cancer-like CIN [61]. We have
mentioned the significant difference between constitu-
tional aneuploidy and the acquired aneuploidy observed
in cancers. Constitutional aneuploidy is a clonal-
chromosome aberration (CCA), whereas many acquired
somatic aneuploidies are nonclonal-chromosome aberra-
tions (NCCAs). In the cellular environment of trisomy
21, trisomy 21 is the dominating “normal” genome, and
any other genomes (including the “normal” 46 XY or
XX karyotype) are relatively “abnormal;” the homeostasis
of trisomy 21 could actually generate less cellular vari-
ation, which explains the resulting low levels of cell-to-
cell variations. Based on this analysis, we suggested that
although specific constitutional aneuploidy alone is not
sufficient for generating numerical CIN, it is necessary
to examine the impact of non-recurrent, stochastic an-
euploidy on generating all types of CIN [62].
Third, many models feature simple types of aneuploidy
(with one extra chromosome within an otherwise nor-
mal karyotype, for example), which is easier to analyze
with repeatable results. In contrast, in the setting of can-
cer evolution, aneuploidy is often coupled with struc-
tural chromosomal changes and/or polyploidy. In
addition, the rate of aneuploidy within the population is
often lower than in clonal populations of model systems,
while for each cell with aneuploidy, the heterogeneity is
higher than cells from model systems (there are often
multiple extra chromosomes, for example). Such differ-
ences between model systems (in which the majority of
cells are isogenic) and cancer samples (which have high
levels of chromosomal and gene mutation heterogeneity)
are reflected by the display of mainly micro-evolutionary
processes in model systems, and a mixture of macro-
evolution plus micro-evolution in real cancer. In a sense,
many model systems mimic a population of the same
species, while real cancer systems mimic a population of
the same species and different species [4, 63–65].
Fourth, when discussing the advantages/disadvantages of
aneuploidy, the majority of studies are focused on growth
status. It should be pointed out that while growth represents
a key feature of cancer, during the earlier stages of cancer
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evolution, growth might not necessarily be the key precon-
dition. The rationale of focusing on cell proliferation in can-
cer research was based on the concept of accumulating gene
mutations during cancer initiation and progression; it was
thus argued that the proliferated cell population could pro-
vide the basis for stepwise cancer evolution. Since the dis-
covery that punctuated cancer evolution is achieved by
genome reorganization events, such as genome chaos, the
rationale of focusing on proliferation has been challenged
[6–8, 50, 56, 66, 67]. Surely, the cancer genome sequencing
project has failed to detect serial, stepwise gene mutation ac-
cumulation in the majority of cancer cases [4, 59, 68]. In
contrast, system instability might not only be an important
earlier event, but in fact the key event. According to the gen-
ome theory [4, 49, 50, 56], genome instability could be the
key driver for all major transitions for cancer evolution, in-
cluding transformation, metastasis, and drug resistance. It is
likely that cellular proliferation contributed by the “onco-
genes” often represents the later events which help cancer
cells to become more dominant cell populations (for more,
see reference [4, 37]). Similar patterns have been observed
in metastasis and drug resistance. Therefore, system instabil-
ity might be the most important aspect for the success of
cancer: new systems’ emergence from normal tissue [69,
70]. Recent single-cell sequencing of breast cancer cells sup-
ports this viewpoint. It was observed that copy number
changes and rearrangements appeared early in tumorigen-
esis. In contrast, point mutations occurred gradually during
tumor evolution (within the micro-evolutionary phase) [71].
Fifth, most current research efforts are focusing on mo-
lecular profiles based on an average population, and outliers
are eliminated or ignored, either by the methods used or
statistical tools. The traditional view of biological research
is to identify patterns from “noise,” without the realization
that the so-called “noise” in fact is heterogeneity, which rep-
resents a key feature of cancer evolution by functioning as
the evolutionary potential. Increased studies have demon-
strated the importance of outliers in cancer evolution, as
cancer is an evolutionary game of outliers [4, 72, 73].
Sixth, in the search for the molecular consequence of
aneuploidy, the focus is still on the genes’ function. Des-
pite the fact that it is hard to make sense out of the data
of altered profiles of a large numbers of genes, few have
realized that aneuploidy, in fact, changes a new
chromosomal-level coding system, which is namely the
system inheritance [16, 37, 66].
Clearly, a new framework is needed to systematically
study aneuploidy in cancer evolution. Since cancer is a
complex adaptive system, and each run of successful evo-
lution can be linked to different genome and gene muta-
tion profiles, more attention needs to be paid to the gap
between initial conditions and final emergence, the envir-
onmental and genome contexts, landscape dynamics, and
system instability-mediated cancer evolutionary potential
[59]. Because cancer evolution requires inheritance, and
involves the emergence of new systems, the following ses-
sion will focus on these issues to redefine inheritance and
the emergent bio-cellular system.
The genome theory of cancer evolution
Based on the ultimate importance of chromosomal aberra-
tions in cancer evolution, especially within the punctuated
phase of macro-cellular evolution, the genome theory of
cancer evolution was introduced with the aim of departing
from the gene mutation theory of cancer [4, 49, 66]. To il-
lustrate how chromosomal changes play a key driving role
in cancer evolution, we have redefined the genomic mean-
ing of karyotype changes, and compared the evolutionary
dynamics between clonal and non-clonal chromosomal ab-
errations [6–8, 64, 74]. Moreover, we have proposed the
use of the genome-mediated evolutionary mechanism to
unify the diverse molecular mechanisms of cancer [55, 75].
Since aneuploidy represents one important type of karyo-
type aberration [15, 74], the principles of genome theory
can be easily applied to aneuploidy research in the context
of somatic evolution, complexity, and how chromosomally-
defined new genomic information plays a driving role for
new system emergence.
System inheritance and aneuploidy
Genes encode proteins, and the sequence of ATGC within
genes is the genetic coding. It has been challenging to
study how aneuploidy affects genetic coding when there
are over a thousand genes involved. Traditionally, atten-
tion has been paid to dosage effects. With the develop-
ment of the technical platform for transcriptome profiling,
it was surprisingly observed that the impact of aneuploidy
is far beyond the dosage effect on genes located on gained
or lost chromosomes [40, 76, 77]. Even more interestingly,
different experimental systems differ in terms of the ob-
served impact. The genomic basis for these unexpected
findings is unknown.
During our watching-evolution-in-action experiments
within an in vitro immortalization model, we constantly ob-
served rapid and massive genome re-organization during
the punctuated phase of cancer evolution [4, 6–8, 78]. Re-
markably, during this phase, mother cells can generate
daughter cells with similar DNA but drastically different
karyotypes. To illustrate the biological meaning of this
karyotype re-organization, we realized that the shattering of
the genome and its subsequent reorganization represent a
powerful means of creating new genomic information. Such
a new mechanism functions above the coding of individual
genes, and perhaps serves to organize gene interaction.
One of the biggest promises of the human genome se-
quencing project was to decipher the blueprint that
makes us human. Unfortunately, we have failed to
achieve this goal following the sequencing phase of the
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genome project. Despite that we know the sequence of
nearly all genes, we have no idea what the genomic blue-
print is. Systems biologists have suggested that the net-
work structure defines the blueprint. But what defines
the network structure in the first place?
Putting all of these questions together, we realized that
the karyotype, in fact, represents a new genomic coding
system, and the blueprint is encoded by the new gen-
omic information which is defined by the order of genes
along and among chromosomes [4, 37, 59]. More specif-
ically, a gene only encodes a specific “part inheritance,”
while a set of the chromosomes of a given species en-
codes the “system inheritance” [16, 66]. Furthermore, we
suggested that the karyotype defines the boundary of a
network structure for a given species, which integrates
the network into the genome-defined system [69, 70].
Further studies suggested that karyotype coding is main-
tained by the function of sex through the meiotic pairing
mechanisms [79–82]. Nearly all significant karyotype ab-
errations will be eliminated by the “reproductive filter,”
which ensures the species identity. In this way, similar
gene content can form different species by creating differ-
ent karyotypes, which determine the physical platform for
gene interactions in the 3-D nucleus [37]. Since different
species display different karyotypes, a species is in fact
preserved by its own chromosomal coding. Furthermore,
it is likely that altered genomic information contributes to
many common and complex diseases [4, 37].
Obviously, aneuploidy alters the karyotype and thus
changes the genomic coding. Despite the fact that much
work is needed to illustrate the details of how aneu-
ploidy changes genomic coding, many experiments sup-
port this idea in principle. For example, aneuploidy not
only changes the overall transcriptomes, but can specif-
ically provide new functions to rescue cells lacking spe-
cific essential genes. When the only copy of the MYO 1
gene was knocked out, yeast should no longer have been
able to survive, as MYO1 encodes the myosin II protein
required for cytokinesis. Surprisingly, however, extensive
polyploidy and aneuploidy (rather than reverse muta-
tion) was demonstrated to rescue the dying populations,
illustrating that genome-level changes can generate
emergent new phenotypes without directly fixing the
specific deleted gene [83]. In other words, re-organizing
the karyotype coding can create functions encoded by
specific genes in different systems. Ample evidence can
be found in current literature [4, 37].
Fuzzy inheritance and aneuploidy
One key feature of cancer is its multiple levels of
genetic/epigenetic/genomic heterogeneity. During time-
course experiments designed to trace karyotype evolu-
tion in vitro, it was documented that the degree of
karyotype heterogeneity can be drastically different
depending on the phases of cellular evolution [6–8]. In
addition, the different extents of karyotype heterogeneity
are evolutionary phase-specific (extremely high within
the punctuated phase and low within the stepwise
phase), suggesting that karyotype heterogeneity is inher-
itable among different cell populations. A similar
phenomenon has been observed from DNA mutation
when discussing the mutant type [84]. Recently, the two
phases of cancer evolution have been confirmed by gene
mutation and copy number profiling [71, 85–88].
Following the characterization of various cancer cell
lines, it became clear that each line displays a different
degree of heterogeneity (reflected as the rate of NCCAs).
To establish the baseline of karyotype heterogeneity in
normal individuals, SKY karyotype analysis was used
after short-term culture of lymphocytes, and the rate of
structural NCCAs was found to be around 1–4%. Inter-
estingly, drug treatment-induced frequencies of NCCAs
are also different among cell lines or individuals with
different levels of genome instability, and elevated fre-
quencies of NCCAs from lymphocytes are detected from
various diseases or illness conditions [17, 19, 89].
The above observations are highly significant in the
context of missing inheritability [90, 91]. It is generally
accepted that phenotype is the result of the interaction
of genotype and environment, but its mechanism is not
clearly understood. For example, for phenotype plasti-
city, the mechanism is unknown. It is also unclear how
different genotypes display different extents of pheno-
typic plasticity, and why environment can win over the
power of genetics or vice versa.
The link between the frequency of NCCAs and pheno-
type heterogeneity has promoted the concept that the
previously regarded “noise,” in fact, represents karyotype
heterogeneity. Further research/synthesis has led to the
realization that it is likely that the coded message at the
karyotype level is heterogeneous in nature, which results
in high phenotypic plasticity.
Important questions were then asked. Is it possible that
inheritance itself is not precise but fuzzy, even for the
coding of a single gene-determined phenotype? Do genetic
elements code a spectrum of potential information rather
than a fixed one? What if these highly penetrant relation-
ships between genotype and phenotype only represent
exceptions in which environmental factors are well-
controlled? Does the major role of environmental factors
select a specific possibility encoded by the genetic coding?
Do stress conditions increase the heterogeneity of pheno-
type by increasing the fuzziness of the genetic coding? To
address these questions, fuzzy inheritance has been intro-
duced by us as the mechanism of various levels of genetic
and epigenetic heterogeneity [4, 37, 70].
Since non-clonal aneuploidy belongs within the category
of NCCAs and represents karyotype heterogeneity, it is
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important to integrate aneuploidy into fuzzy inheritance.
Despite the fact that the frequencies of aneuploidy in vari-
ous normal tissues are low, when combined with other
NCCAs, the level of altered karyotypes is rather high, espe-
cially under stress conditions [50, 92, 93, 94]. In addition,
the drastic difference between the spontaneous rate of an-
euploidy in cells from normal tissue and in those from can-
cers supports the idea that specific cell populations display
different degrees of fuzzy inheritance which are related to
aneuploidy. For example, the mis-segregation rate in a
stable, diploid cell line is one chromosome per 100–1000
cell divisions. In contrast, the mis-segregation rate in cul-
tured cancer cells with CIN is approximately once every
1–5 divisions [95–97]. More remarkably, during the gen-
ome chaos phase, almost all cells display a high rate of
mis-segregation with large number of aneuploidies, plus all
sorts of karyotype variants [6, 50, 67]. The high degree of
fuzzy inheritance in cancer, in fact, can also explain why
non-clonal aneuploidy is a common feature of even later
stages of cancer. All tumors are under high stress from sur-
rounding tissues or higher systems, so fuzzy inheritance-
mediated karyotype heterogeneity is essential for tumor
survival and further progression. Clearly, how aneuploidy
quantitatively contributes to fuzzy inheritance-mediated
genomic heterogeneity needs further study.
The relationship between cellular adaptation and trade-off
Traditionally, aneuploidy has long been blamed as the result
of bio-errors. Most of the molecular evidence supports this
viewpoint, as when specific genes are dysfunctional as a re-
sult of experimental manipulation, a phenotype of increased
aneuploidy can be observed. Many gene mutations involving
cell cycle/chromosomal integrity can achieve the same
phenotype. While the baseline of aneuploidy in normal indi-
vidual tissues is low in many cases, in some tissue types, the
spontaneous aneuploidy is high. Moreover, the overall rate of
NCCAs is not low at all in most normal tissues.
Obviously, the higher than expected frequency of karyo-
type changes, including aneuploidy, cannot simply be ex-
plained as bio-error. In recent years, the biological
significance of these seemingly random genetic “back-
grounds” were studied, which has led to the appreciation of
genomic heterogeneity in cancer evolution. Further synthe-
sis suggests a relationship between stress-induced NCCAs
and the advantages offered by their presence for cellular
adaptation, as well as the trade-offs caused by their pres-
ence in cancer evolution and possibly in other disease con-
ditions [4, 92]. Moreover, many diseases are the results of
genomic variants which do not fit the current environ-
ments. Due to the dynamics of environments and the na-
ture of fuzzy inheritance, it is impossible to eliminate all of
these variants. Paradoxically, these genomic variants might
be necessary for the species’ long-term survival, and they
should be considered as a life insurance policy despite their
high costs. Such a concept of trade-off not only addresses
the key evolutionary mechanism of many diseases including
cancer, but may also provide some answers to patients who
ask the “why me” question. In a sense, cancer as an evolu-
tionary trade-off can be illustrated by different perspectives:
at the mechanistic level, cancers are the by-products of evo-
lution (that is, the same mechanisms which make us hu-
man also make cancer successful); at the species level, as
population heterogeneity is important for species survival,
an individual with high genome instability can be consid-
ered as paying the price for our species; and at the individ-
ual level, most bio-features, including lifestyle, could be
beneficial in some aspects and yet harmful in other aspects.
Even for non-clonal aneuploidy-mediated cellular hetero-
geneity, while this phenomenon can provide a potential
advantage for cellular adaptation, it can also, paradoxically,
generate non-specific system stress, which can further pro-
duce more genetic and non-genetic variants which favor
the disease condition [4]. Based on this rationale, we have
attempted to use type I and type II CIN to unify diverse
gene mutations under the principle of CIN-mediated
cancer evolution, as many gene mutations and molecular
pathways which are not directly involved in maintaining
genome integrity can still be linked to CIN [50].
Emergence and luck
The unpredictability of emergence represents a common
challenge for using parts characterization to predict
phenotype at higher levels in a complex adaptive system.
How aneuploidy triggers the successful evolution of can-
cer, especially during the phase transitions, is almost un-
known. The situation worsens when the type of
aneuploidy is non-clonal, and when both the context of
other types of genetic changes and cellular environments
keeps changing. For example, different tissues can tolerate
different degrees of aneuploidy; aneuploidy can be de-
tected at the early development stage with high frequen-
cies, but the developmental process can overcome them,
whereas the impact of aneuploidy can become serious
during cancer evolution later in life; even in tissues that
are sensitive to aneuploidy, most instances of aneuploidy
will not lead to cancer. It seems that in different tissue
types, different stages of development and aging, and dif-
ferent physiological and pathological processes, there are
different “roles” for the cellular society which favor differ-
ent types of emergence [19, 37]. For example, in a normal
physiological cellular society, the average profile can over-
rule outliers, while in the setting of cancer evolution and
under high stress, the outliers may triumph.
To understand how non-clonal karyotype aberrations can
contribute to the emergence of cancer evolution, we pro-
posed that instances of non-clonal aneuploidy, like other
types of non-clonal karyotype aberrations, serve as hetero-
geneous agents that can impact the emergent properties of
Ye et al. Molecular Cytogenetics  (2018) 11:31 Page 8 of 13
the cellular evolution. While the details of how aneuploidy
affects emergence are not yet known, this model illustrates
the importance of how even a portion of non-clonal aneu-
ploidy can change the emergence process (Fig. 1). A similar
general model of how the heterogeneity of genetic agents
impacts diseases has been proposed to explain how NCCAs
can contribute to different diseases [18, 98].
Due to the complex combinations of aneuploidy and the
genetic and environmental contexts, a vast majority of these
combinations will not directly lead to cancer’s success, as
they are either not powerful enough to contribute to the
phase transition which leads to cancer, or they are elimi-
nated by system constraint. For example, it was recently
demonstrated that the complex karyotypes derived from
aneuploidy can trigger the immune system to eliminate
them (Table 3). Another example is drug therapy in which
a high dosage of drugs is used. The majority of the cancer
cells will be eliminated by the initial drug treatment, and
only a tiny portion of the cancer cells can survive (through
the formation of genome chaos). It is extremely challenging
to predict which aberrations will be successful, even though
drug-resistant clones often arise.
As a consequence of the highly heterogeneous nature of
karyotypes featuring aneuploidy, as well as the diverse
genomic/environmental contexts involved, most genomic
aberrations will not lead to the success of cancer, despite
their potential. A “perfect storm” is needed for any cancer
to be successful. Under such conditions, luckiness or un-
luckiness can be considered agents which impact the
emergent properties.
Such interplay during cancer evolution is ultimately
responsible for the emergence of a new genome system
from normal tissue, and aneuploidy-mediated genome
re-organization plays a key role for creating these new
systems [4, 37, 66]. For altered cells to become cancer
cells, they have to complete many key transitions, in-
cluding immortalization, transformation and metastasis,
all of which require the emergence of different genome
systems; gene mutation alone is not sufficient for creat-
ing a new system. The alteration of system inheritance
and the increased degree of fuzzy inheritance mainly
contribute to the macro-cellular evolution which leads
to new systems. In contrast, genes that promote cell pro-
liferation can expand cancer cell populations following
the formation and selection of cancer cells with unique
karyotype-defined systems (Fig. 2).
Conclusion and future research
Within the framework that represents cancer as a com-
plex adaptive system, the following elements become
highly important for understanding both the key feature
and common mechanism of cancer: internal and external
stress-mediated adaptation and its trade-off (trigger fac-
tors); the multiple levels of genetic/environmental hetero-
geneity (essential conditions for cancer evolution); the
involvement of system inheritance and fuzzy inheritance
(how genomics works during cancer evolution); the two
phases of cancer evolution (the mechanism of cellular
evolution and the relationship between gene/epigene and
genome changes); the emergence of new, karyotype-
defined systems (the formation of a cancer seed and the
importance of NCCAs and outliers); and the population
of cancer cells that become clinically significant (the dom-
inance of cancer). It is necessary to integrate these ele-
ments during studies of aneuploidy.
Despite the recent exciting progress of aneuploidy re-
search, some great challenges remain. Simply focusing on
the molecular characterization of agents at lower levels is
neither sufficient for understanding the emergent proper-
ties of a complex adaptive system nor for predicting the
contribution of aneuploidy to cellular evolution.
To change the status quo, the crucial first step is to ac-
knowledge the fundamental limitation of the reductionist
approach in aneuploidy research, as there is no precise,
predictable relationship between an understanding of the
individual mechanism of aneuploidy and clinical certainty,
nor between many diverse individual agents and the emer-
gent properties of cancer evolution. It is thus equally diffi-
cult to search for patterns based on diverse molecular
pathways. In addition, the dynamic interaction of average
cells and outliers further complicates this prediction. To
Fig. 1 The illustration of how the heterogeneity of aneuploidy impacts
the emergent properties of cellular populations. Since there is no
direct correlation from individual agents to the emergent properties,
the final properties are based on the collective emergence of all
agents. Circles represent cells with normal karyotypes, triangles
represent cells with non-clonal aneuploidy, and arrows represent
pathways among agents. These variable properties are the potential
basis for cancer evolution (modified from reference [19])
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make sense of this complexity and to increase predictability,
a better strategy is to consider aneuploidy as an agent and
cancer as a complex adaptive system. Expectations regarding
the predictive power of aneuploidy must also change, as the
success of cancer evolution depends on both evolutionary
potential (which can be measured) as well as on chance or
accidents (which are hard to predict) [99, 100]. The import-
ance of special “circumstances” or “accidents” in evolution-
ary success is receiving our increased attention [4, 37, 66].
An innovative type of biomarkers is needed to integrate
aneuploidy with other karyotype alterations, and these
should be used to measure evolutionary potential (based
on the degree of heterogeneity and karyotype complexity)
rather than specific pathways. This approach will likely
bridge the gap between basic research and clinical impli-
cations. There are some examples of applying aneuploidy
in clinical analysis [101]. High somatic copy number alter-
ations in melanoma patients have recently been linked
with less effective response to immune checkpoint block-
ade anti–CTLA-4 (cytotoxic T lymphocyte–associated
protein 4) therapy [52]. Clearly, aneuploidy status is asso-
ciated with response to precise immunotherapy. We have
engaged in the effort of using NCCAs (mainly structural
NCCAs) to monitor clinical outcomes. One approach is
to measure an individual’s overall genome instability and
its linkage to cancer status. We have observed a strong
correlation between the frequencies of structural NCCAs
from short term lymphocytes culture and prostate cancer
[37]. This work has expanded into other health conditions
[17]. A similar concept of monitoring overall genome in-
stability to detect cancer can be found in literature
involving telomere length and the overall chromosomal
aberration rate [102–107]. More aneuploidy data should
be integrated into this effort. In particular, since chromo-
some data (CIN statuses, for example) have much more
clinical predictive power than sequenced gene mutation
data [4, 50–53, 74], bioinformaticians should be encour-
aged to search for new platforms for mining sequences in
the context of evolutionary potential, through the use of
AI (artificial intelligence) approaches. For example, this
strategy could be used to search for the principle of how
aneuploidy changes the blueprint, its overall impact on
the gene network, and the quantitative contribution of ele-
ments for the higher level of emergence.
Further research is also needed to compare emergence
based on average profiles and outliers with various degrees
of system stress. Such analysis needs to be done within the
context of the cellular society concept [4, 108]. As for the
technical platforms, new monitoring methods should be
developed to study single cells, especially to profile non-
dividing cell populations. Recently, the CRISPR/Cas9 sys-
tem has been used to eliminate targeted chromosomes.
This new approach offers an effective way to develop ani-
mal models with aneuploidy, which can be used as a po-
tential therapeutic strategy for human aneuploidy diseases
[109]. Certainly, among these advances, one immediate
priority is to illustrate how aneuploidy triggers structural
alterations of the karyotype and provides the maximal di-
versity and plasticity needed for new system emergence
and domination. For example, can aneuploidy lead to gen-
ome chaos [110]? How does the heterogeneity of aneu-
ploidy impact the newly emergent karyotype?
Fig. 2 The proposed timeline that illustrates the relationship between various molecular mechanisms (summarized by the hallmarks of cancer,
modified from reference [50, 139]), aneuploidy, CIN (often coupled with other karyotype alterations such as structural alterations and polyploidy),
macro-evolution, micro-evolution and the clinically detectable tumor. As NCCAs can be detected from earlier developmental stages, the
relationship between various molecular mechanisms and aneuploidy is less clear. It is clear, however, that there is a complex, interactive
relationship. Furthermore, elevated CIN is important for triggering macro-cellular evolution, followed by micro-cellular evolution, leading ultimately
to the proliferation of the cancer cells with the winning genome. This diagram highlights the complex, dynamic relationship between aneuploidy,
CIN and the two phases (macro and micro) of cancer evolution
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Finally, and perhaps most importantly, the ultimate
goal of establishing better concepts and platforms for
cancer research is to apply them in the clinic. Further
studies are needed to apply this new understanding of
aneuploidy for patient stratification, directing therapy
schedules, and predicting drug resistance.
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